1Hideki Hirabayashi,Makiya Nishikawa,Yoshinobu Takakura,Mitsuru Hashida. Development and Pharmacokinetics of Galactosylated Poly-L-Glutamic Acid as a Biodegradable Carrier for Liver-Specific Drug Delivery[J] 1996,Pharmaceutical Research(6):880～884
2Gregoriadis G. Liposome Technology ( Vol 3 ) [ M ]. Boca Raton: CRC Press, 1984:75-94.
3Jones PF, Jakubowicz T, Pitossi FJ, et al. Molecular cloning and identification of a serine/threonine protein kinase of the second messenger subfamily [ J ]. Proc Natl Acad Sci USA, 1991, 88(10) :4171.
4Datta SR, Brunet A, Greenberg ME. Cellular survival : a play in three Akts[J]. Genes Dev, 1999, 13(22) : 2905.
5Perez - Soler R. Phase Ⅱ clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI -774) in non- small- cell lung cancer [ J]. Clin Lung Cancer, 2004, 6 ( Suppl 1) :S20.
6Fuster LM, Sandler AB. Select clinical trials of erlotinib ( OSI -774) in non - small - cell lung cancer with emphasis on phase Ⅲ outcomes[J]. Clin Lung Cancer ,2004,6(Suppl 1 ):S24.
7Gatzemeler U, Rosell R, Ramlau R, et al. Cetuximab (C225) in combination with cisplatin/vinorelbine vs cisplatin/ vinorelbine alone in the first- line treatment of patients (pts) with epidermal growth facor recoptor (EGFR) positive advanced non- small- cell lung cancer (NSCLC) [ abstract no. 2582 ] [J]. Pro Am Soc Clin Oncol , 2003, 22: 642.
8Giles F, Estey E, O'Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia[J]. Cancer, 2003, 98 (10) : 2095.
9Emmanouilides C. Radio immunotherapy for non- Hodgkin's lymphoma[J]. Sem in Oncol, 2003, 30 (4):531.
10Koivunen E, Arap W, Rajotte D, et al. Identification of receptor ligands with phage display peptide libraries [ J]. J Nucl Med, 1999, 40(5) : 883.
